Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Lijun Zhang et al.|The Lancet|2014Cited by 4.7k
Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Joyce O’Shaughnessy, Javier Cortés et al.|New England Journal of Medicine|2020Cited by 3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Fátima Cardoso, Eric P. Winer, D. Fenech et al.|Annals of Oncology|2016Cited by 2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Alan S. Coates, Binghe Xu, Andrew Tutt et al.|Annals of Oncology|2015Cited by 1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Martine Piccart, Marion Procter et al.|The Lancet|2007Cited by 1.5k